ArriVent reports $326M in liquidity, topline Phase 3 FURVENT results expected mid-2026

ArriVent BioPharma (NASDAQ:AVBP) ended the first quarter on March 31, 2026, with $326.4 million in cash, cash equivalents, and short-term investments.

Management indicated that this capital reserve is sufficient to fund operations into the fourth quarter of 2027, covering several critical regulatory and clinical milestones.

For the quarter, the company reported a net loss of $43.3 million, driven primarily by research and development expenses of $37.6 million as late-stage global trials reached peak enrollment.

The company’s lead candidate, firmonertinib, remains the primary focal point for investors ahead of anticipated topline results from the Phase 3 FURVENT trial in mid-2026.

The study is evaluating firmonertinib as a first-line treatment for patients with NSCLC harboring EGFR exon 20 insertion mutations.

Simultaneously, the drug has moved closer to commercialization in international markets, receiving accelerated approval from China’s National Medical Products Administration (NMPA) for second-line treatment in the same patient population.

Beyond its lead program, ArriVent has successfully transitioned into a multi-asset clinical organization following recent regulatory clearances.

The company received FDA Investigational New Drug (IND) clearances for ARR-217 and its dual-target antibody-drug conjugate (ADC), ARR-002.

Clinical activity for ARR-002 is expected to accelerate in the coming months, with the first patient dosing targeted for the second half of 2026.

General and administrative expenses for the quarter stood at $8.5 million, reflecting the scaled infrastructure required to support these expanding global operations.